High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Inclusion criteria

• ✓. Patients with any of the following hematologic malignancies:
• ✓. Patient age ≥ 18 years
• ✓. Karnofsky Performance status ≥ 70%
• ✓. Patients must also be suitable to receive a reduced-intensity (RIC) conditioning regimen at the discretion of the treating physician. While there are not universally accepted or validated cut-off criteria of age, performance status, or hematopoietic cell transplantation-comorbidity index (HCT-CI) for suitability for RIC, RIC transplants should be considered for patients 60 years and older, and for patients \<60 years who are "less fit", e.g., KPS \<90% and/or HCT-CI ≥ 3 due to lower non-relapse mortality associated with RIC.
• ✓. Patients receiving allogeneic peripheral blood stem cell (PBSC) grafts from HLA-matched (5/6 and 6/6 matches) siblings or matched unrelated donors (7/8 or 8/8 matches at HLA-A, B, C, DRB1 by high resolution typing) are included. All grafts will be unmanipulated (i.e., no T cell depleted or CD34 selected grafts). In addition, donors should meet institutional criteria for donation of PBSC, as well as the screening and eligibility criteria of the National Marrow Donor Program (NMDP) for unrelated donors, and the requirements of the United States Food and Drug Administration for Human Cell, Tissue, or Cellular or Tissue-based Products (HCT/P) (21 CFR Part 1271).
• ✓. Required baseline laboratory values within 16 days prior to admission:
• ✓. Required baseline values within 60 days prior to admission:
• ✓. No evidence of HIV infection (Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.)

Exclusion criteria